title: The shrinking renal replacement therapy "break-even" point.
abstract: BACKGROUND
  This study examines the current cost of live donor (LD) transplantation at our institution, and compares it with that of dialysis.
  
  
  METHODS
  The study population consisted of 184 consecutive adult recipients of laparoscopically procured LD kidney transplants. Cost-containment measures instituted during this series included elimination of routine postoperative antilymphocyte induction and an accelerated discharge clinical pathway with planned discharge of the recipient on postoperative day (POD) 2. Costs of the transplants to Medicare were estimated from hospital charges, readmission rates, and immunosuppressant usage. These were compared with published costs of dialysis to Medicare in terms of a fiscal transplant-dialysis break-even point.
  
  
  RESULTS
  Kaplan-Meier patient and graft survival rates at 1 year were 97 and 93%, respectively. Among patients followed for at least 90 days and treated with no induction and either cyclosporine-mycophenolate mofetil or tacrolimus-mycophenolate mofetil, acute rejection rates were low (27.6 and 13.9%, respectively). In the last 124 patients, 32.3% were discharged by POD 3 and 71.8% by POD 6, with corresponding mean transplant hospital charges (excluding organ acquisition) of $11,873 and $17,350, respectively. The 30-day readmission rate for patients discharged on the accelerated pathway by POD 3 was only 16%. The least expensive subgroup in the present study (30% of patients) was that of patients discharged by POD 6 and not readmitted during the first year; the break-even point with dialysis costs was calculated as 1.7 years after the transplant.
  
  
  CONCLUSIONS
  The cost of LD transplants can be safely reduced by elimination of routine postoperative anti-lymphocyte immune induction and by an early discharge clinical pathway. Uncomplicated LD kidney transplants, meaning those with a short length of stay in the hospital after transplantation and no need for readmission within the first year, accrue savings over dialysis within 2 years.
authors.affiliation: Department of Surgery, University of Maryland, Baltimore, USA. gschweitzer@surgery1.umaryland.edu
authors.forename: E J
authors.initials: EJ
authors.lastname: Schweitzer
authors.forename: A
authors.initials: A
authors.lastname: Wiland
authors.forename: D
authors.initials: D
authors.lastname: Evans
authors.forename: M
authors.initials: M
authors.lastname: Novak
authors.forename: I
authors.initials: I
authors.lastname: Connerny
authors.forename: L
authors.initials: L
authors.lastname: Norris
authors.forename: J O
authors.initials: JO
authors.lastname: Colonna
authors.forename: B
authors.initials: B
authors.lastname: Philosophe
authors.forename: A C
authors.initials: AC
authors.lastname: Farney
authors.forename: B E
authors.initials: BE
authors.lastname: Jarrell
authors.forename: S T
authors.initials: ST
authors.lastname: Bartlett
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006084:Graft Rejection; D017722:Hospital Charges; D006801:Humans; D016030:Kidney Transplantation / Q000191:economics*; D007902:Length of Stay; D008297:Male; D006278:Medicare; D008875:Middle Aged; D010359:Patient Readmission; D006435:Renal Dialysis; D014481:United States